title: Gene expression profiling: decoding breast cancer.
abstract: Gene expression assays that are used in daily clinical practice for treating early breast cancer patients have been introduced in the clinic only recently. This review discusses the development of these arrays, summarizes the validation of those that are commercially available and indicates how the information provided by these assays can help in the care of patients. The review also provides an extensive overview of commercially available assays focusing on MammaPrint, the first and only assay for breast cancer management that has been cleared by the FDA.
authors.affiliation: Department of Medical Affairs, Agendia BV, Science Park 406, Amsterdam, The Netherlands. femke.desnoo@agendia.com
authors.forename: Femke
authors.initials: F
authors.lastname: de Snoo
authors.forename: Richard
authors.initials: R
authors.lastname: Bender
authors.forename: Annuska
authors.initials: A
authors.lastname: Glas
authors.forename: Emiel
authors.initials: E
authors.lastname: Rutgers
mesh_terms: D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D006801:Humans; D046228:Microarray Analysis; D025202:Molecular Diagnostic Techniques; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D011933:Reagent Kits, Diagnostic; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D011933:Reagent Kits, Diagnostic